Stephen Kaplita

TL;DR: Aripiprazole shows a favorable safety and tolerability profile with low potential for EPS, weight gain, prolactin elevation, QT(c) prolongation, and sedation and may offer benefits in schizophrenia treatment.

TL;DR: Aripiprazole demonstrated superior efficacy to placebo in the treatment of patients with bipolar I disorder presenting with acute manic or mixed episodes, and exhibited a favourable safety and tolerability profile.

TL;DR: Nefazodone was associated with normal objective, and clinician- and patient-rated assessments of sleep when compared with fluoxetine, and these differential sleep EEG effects are consistent with the notion that nefzodone and fluoxettine may have somewhat different modes and spectra of action.

TL;DR: Avagacestat did not demonstrate efficacy and was associated with adverse dose-limiting effects in this PDAD population, which had higher rates of clinical progression to dementia and greater brain atrophy compared with CSF biomarker-negative participants.

TL;DR: Imaging and biochemical studies show that schizophrenia is characterized by a number of morphological, hemodynamic, and neurochemical abnormalities within systems integrating the cortex, temporal lobes, and various limbic structures, and neurotransmitters serotonin, dopamine, and glutamate play a significant role in the disease-associated decrement.